Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Biotechnology

Life Sciences

Therapeutics

Ampersand Biomedicines

Jason Gardner

Daniel Blom

Yann Echelard

Raffi Afeyan

Luciano Rossetti

The Leadership Team at Ampersand Biomedicines is responsible for setting the strategic direction and overseeing the implementation of the company's innovative approach to programmable medicines. This team, composed of experts in science, research, and business, collaborates to drive the development of the AND™ Platform, ensuring that the technology effectively targets diseases while minimizing impact on healthy tissue. Their collective vision and expertise foster a culture of scientific excellence and innovation, guiding Ampersand in its mission to revolutionize therapeutic design.

Leadership Team

Research and Development

Leadership Team

About

Team members

Other teams at Ampersand Biomedicines

Research and Development